cGAS and cancer therapy: a double-edged sword

Acta Pharmacol Sin. 2022 Sep;43(9):2202-2211. doi: 10.1038/s41401-021-00839-6. Epub 2022 Jan 18.

Abstract

Cyclic guanosine monophosphate-adenosine monophosphate adenosine synthetase (cGAS) is a DNA sensor that detects and binds to cytosolic DNA to generate cyclic GMP-AMP (cGAMP). As a second messenger, cGAMP mainly activates the adapter protein STING, which induces the production of type I interferons (IFNs) and inflammatory cytokines. Mounting evidence shows that cGAS is extensively involved in the innate immune response, senescence, and tumor immunity, thereby exhibiting a tumor-suppressive function, most of which is mediated by the STING pathway. In contrast, cGAS can also act as an oncogenic factor, mostly by increasing genomic instability through inhibitory effects on DNA repair, suggesting its utility as an antitumor target. This article reviews the roles and the underlying mechanisms of cGAS in cancer, particularly focusing on its dual roles in carcinogenesis and tumor progression, which are probably attributable to its classical and nonclassical functions, as well as approaches targeting cGAS for cancer therapy.

Keywords: cGAS; tumor suppression; tumor promotion; cancer therapy.

Publication types

  • Review

MeSH terms

  • Carcinogenesis / metabolism
  • Cytosol / metabolism
  • DNA / metabolism
  • Humans
  • Immunity, Innate
  • Interferon Type I* / metabolism
  • Neoplasms*
  • Nucleotidyltransferases / genetics
  • Nucleotidyltransferases / metabolism

Substances

  • Interferon Type I
  • DNA
  • Nucleotidyltransferases
  • cGAS protein, human